research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Jake Carlisle (born 1 October 1991) is a former professional Australian rules footballer who played 66 games for the St Kilda Football Club in the Australian Football League (AFL) until his retirement at the end of the 2021 season. He previously played 85 games for the Essendon Football Club from 2010 to 2015.
== Career == In 1999, Sherrill joined the faculty of the school of chemistry and biochemistry at Georgia Tech. He joined the school of computational science and engineering as a joint faculty member in 2006. He became associate director of Georgia Tech's Institute for Data Engineering and Science (IDEaS) in 2017. He has been an associate editor of The Journal of Chemical Physics since 2009.
=== Municipal administration === The number of inhabitants in Le Havre is between 150,000 and 199,999 so the number of councillors is 59 members. The mayor, 41 aldermen and 17 deputies form the council of Le Havre elected in 2008. It meets on average once a month at the town hall. The debates are generally public except for certain proceedings. Le Havre has experienced many territorial extensions by annexing neighbouring communes:
A year into his term, Mahathir's approval ratings had fallen as the economy slowed and several planned reforms, such as abolishing capital punishment and the Sedition Act 1948, were not realised amid divisions in the coalition. Mahathir announced the Shared Prosperity Vision 2030 in October 2019, which set out for Malaysia to become a high income country by 2030. Another priority of his administration was a more transparent approach to defence. The government prepared the country's first defence policy white paper outlining long-term plans for the country.
Sources: en.wikipedia.org
== Properties == Protactinium is an actinide positioned in the periodic table to the left of uranium and to the right of thorium, and many of its physical properties are intermediate between its neighboring actinides. Protactinium is denser and more rigid than thorium, but is lighter than uranium; its melting point is lower than that of thorium, but higher than that of uranium. The thermal expansion, electrical, and thermal conductivities of these three elements are comparable and are typical of post-transition metals. The estimated shear modulus of protactinium is similar to that of titanium. Protactinium is a metal with silvery-gray luster that is preserved for some time in air. Protactinium easily reacts with oxygen, water vapor, and acids, but not with alkalis. At room temperature, protactinium crystallizes in the body-centered tetragonal structure, which can be regarded as distorted body-centered cubic lattice; this structure does not change upon compression up to 53 GPa. The structure changes to face-centered cubic (fcc) upon cooling from high temperature, at about 1200 °C. The thermal expansion coefficient of the tetragonal phase between room temperature and 700 °C is 9.9×10−6/°C. Protactinium is paramagnetic and no magnetic transitions are known for it at any temperature. It becomes superconductive at temperatures below 1.4 K. Protactinium tetrachloride is paramagnetic at room temperature, but becomes ferromagnetic when cooled to 182 K.
It causes similar alterations on EEG readings and sleep architecture as benzodiazepines and causes disturbances in sleep architecture on withdrawal as part of its rebound effect. Zopiclone reduces both delta waves (slow-wave sleep) and the number of high-amplitude delta waves whilst increasing low-amplitude waves. Zopiclone reduces the total amount of time spent in REM sleep as well as delaying its onset. In EEG studies, zopiclone significantly increases the energy of the beta frequency band, increasing stage 2. Zopiclone is less selective to the α1 site and has higher affinity to the α2 site than zaleplon. Zopiclone is therefore very similar pharmacologically to benzodiazepines.
1973); British-Israeli politician, media expert, journalist, media-spokesperson, policy maker; Deputy Mayor of Jerusalem in charge of foreign relations, international economic development and tourism; co-founder of UAE–Israel Business Council; appointed by Israel's foreign minister Eli Cohen as special envoy for innovation; has written editorials, commentary, and op-ed columns for The Telegraph, Jerusalem Post, La Voz de Galicia, Times of Israel, Haaretz, Ynet News, Gulf Business, Arutz Sheva/Israel National News, Algemeiner Journal, Jewish Journal (Los Angeles), Jewish News, JNS, Jüdische Allgemeine, Salem Radio Network News, The Media Line, The Detroit Jewish News, Jewish Policy Center, Israel Behind The News, The Jewish World, Jewish Chronicle; previously served as president of King's College Jewish Society; was barrister at Middle Temple; served as campaign director at World Jewish Relief; served as senior associate with American Jewish Joint Distribution Committee; CEO of international strategic communications firm, Message Experts; worked with U.S. State Department on embassy in Jerusalem; one of founders of UAE–Israel Business Council. Dan Neidle (b.
== Medical uses == In the United States imipenem/cilastatin/relebactam is indicated for the treatment of people with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options. It is also indicated to treat HABP/VABP in adults 18 years of age and older. In the European Union it is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
A phylogenomic and geochemical analysis of proteins plausibly traced to the LUCA shows that the ionic composition of its intracellular fluid is identical to that of hot springs. The LUCA likely was dependent upon synthesized organic matter for its growth. Experiments show that RNA-like polymers can be synthesized in wet-dry cycling and UV light exposure. These polymers were encapsulated in vesicles after condensation. Potential sources of organics at hot springs might have been transported by interplanetary dust particles, extraterrestrial projectiles, or atmospheric or geochemical synthesis. Hot springs could have been abundant in volcanic landmasses during the Hadean.
Sources: en.wikipedia.org
== Constituents == The main compounds in skullcap are flavonoids. Isolated chemical compounds include wogonin, wogonoside, and 3,5,7,2',6'-pentahydroxyl flavanone found in Scutellaria. Other constituents include baicalin, apigenin, oroxylin A, and scutellarein.
=== CTLA-4 blockade === The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 to treat melanoma. It blocks the immune checkpoint molecule CTLA-4. As of 2012, clinical trials have also shown some benefits of anti-CTLA-4 therapy on lung cancer or pancreatic cancer, specifically in combination with other drugs. In on-going trials the combination of CTLA-4 blockade with PD-1 or PD-L1 inhibitors is tested on different types of cancer. However, as of 2015 it is known that patients treated with checkpoint blockade (specifically CTLA-4 blocking antibodies), or a combination of check-point blocking antibodies, are at high risk of having immune-related adverse events such as dermatologic, gastrointestinal, endocrine, or hepatic autoimmune reactions. These are most likely due to the breadth of the induced T-cell activation when anti-CTLA-4 antibodies are administered by injection in the bloodstream. A 2024 cohort study of ICI use during pregnancy showed no overreporting of specific adverse effects on pregnancy, fetal, and/or newborn outcomes, interestingly. Using a mouse model of bladder cancer, researchers have found that a local injection of a low dose anti-CTLA-4 in the tumour area had the same tumour inhibiting capacity as when the antibody was delivered in the blood. At the same time the levels of circulating antibodies were lower, suggesting that local administration of the anti-CTLA-4 therapy might result in fewer adverse events.
== Costs == Bone graft procedures consist of more than just the surgery itself. The complete three-month total cost of a complex posterolateral lumbar spine fusion bone graft supplemented with graft extenders ranges from a mean of approximately US$33,860 to US$37,227. This price includes all visits in and out of the hospital for three months. Besides the cost of the bone graft itself (ranging from US$250 to US$900) other expenses for the procedure include: outpatient rehabilitation fees (US$5,000 to US$7,000), screws and rods (US$7,500), room and board (US$5,000), operating room (US$3,500), sterile supplies (US$1,100), physical therapy (US$1,000), surgeon's fees (average US$3,500), anesthesiologist fees (approximately US$350 to US$400 per hour), medication charges (US$1,000), and additional fees for services such as medical supplies, diagnostic procedures, equipment use fees, etc.
On 17 May 2002, Norris injected patient Vera Wilby with an overdose of the painkiller morphine to make her drowsy (as recorded in the hospital notes and later admitted by Norris), despite the fact that she was in no pain and needed no morphine. He then administered insulin before going off shift, for no apparent medical reason. Ninety minutes after he went off shift, Wilby was found to be semi-conscious and suffering from a sudden hypoglycaemic attack, but she survived. Wilby had dementia and had been seen as a "difficult" patient by Norris. On 12 June, another patient, Doris Ludlam, was admitted to Norris's ward with a broken hip. On 25 June, she was also given an unnecessary injection of morphine (as recorded in the hospital notes and later admitted by Norris) followed by an overdose of insulin, and Norris then again went off shift. She was discovered in a coma 40 minutes after he went off shift. 88-year-old Bridget Bourke, who had been admitted to the ward on 16 June also with a broken hip, was then discovered at 3:10 a.m. on 21 July (by Norris) suffering from a hypoglycaemic attack; she died the next day. Norris was then transferred to St James's University Hospital, and on 10 October 2002, 79-year-old Irene Crookes was admitted to Norris's new ward with a broken hip. Despite Norris recording that her condition was improving, he supposedly found her "totally unresponsive" just before 6 a.m. on 19 October, having suffered a hypoglycaemic attack. She died the next day.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.